SEC Comment Letter 0000000000-25-000593 to Summit Therapeutics Inc. (SMMT) (CIK 0001599298) (SMMT)
Summit Therapeutics Inc. (SMMT) (CIK 0001599298)
Date: Jan. 21, 2025 · CIK: 0001599298 · Accession: 0000000000-25-000593
AI Filing Summary & Sentiment
File numbers found in text: 001-36866
Letter
January 21, 2025 Robert Duggan Chairman and Co-Chief Executive Officer Summit Therapeutics, Inc. 601 Brickell Key Drive, Suite 1000 Miami, FL 33131 Re:Summit Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-36866 Dear Robert Duggan: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
January 21, 2025
Robert Duggan
Chairman and Co-Chief Executive Officer
Summit Therapeutics, Inc.
601 Brickell Key Drive, Suite 1000
Miami, FL 33131
Re:Summit Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-36866
Dear Robert Duggan:
We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences